Docoh
Loading...

MNPR Monopar Therapeutics

Filed: 3 Jun 21, 8:01am
 
 
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d)
 
of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): June 3, 2021
 
 
MONOPAR THERAPEUTICS INC.
 
(Exact name of registrant as specified in its charter)
 
 
 
  Delaware   001-39070   32-0463781
  (State or other jurisdiction of incorporation)   (Commission File Number)  
  (I.R.S. Employer Identification No.)
 
 

  1000 Skokie Blvd., Suite 350, Wilmette, IL  60091 
  60091
  (Address of principal executive offices)    (Zip Code)
 

 
 
 
(847) 388-0349
 
Registrant’s telephone number, including area code
 
N/A
 
(Former name or former address, if changed since last report)
 
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value MNPR  
The Nasdaq Stock Market LLC 
(Nasdaq Capital Market)
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
 
 
 
 
 
 
 
 
Item 7.01 Regulation FD Disclosure
 
 
                 On June 3, 2021, Monopar Therapeutics Inc. issued a press release announcing a collaboration agreement with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer. MNPR-202 was designed to retain the same potentially non-cardiotoxic backbone as camsirubicin but is modified at other positions which may enable it to work in certain cancers that are resistant to camsirubicin and doxorubicin.
 
 
The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
 
 
 
 
Item 9.01 Financial Statements and Exhibits

 
Exhibit No.
 
Description
 99.1  
 
 
 
 
 
 
 
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 

 
Monopar Therapeutics Inc.
 
    
Date: June 3, 2021
By:  
/s/  Kim R. Tsuchimoto
 
  
Name: Kim R. Tsuchimoto  
 
  
Title:  Chief Financial Officer, Secretary and Treasurer